芬瑞诺减少了心脏脏代谢综合征的全谱新发性心房动:FINE-HEART聚合分析
Maria A Pabon1, Gerasimos Filippatos2, Brian L Claggett1
1Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Journal of the American College of Cardiology
|April 30, 2025
概括
非类固醇矿物质皮质体受体对抗剂 (MRA) 的芬瑞显著降低了心脏-脏-代谢谱的患者新发性心房 (AF) 或心房 (AFL) 的风险. 这一发现突出了fineerenone的重要意义.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
背景情况:
- 矿物质皮质类受体抗剂 (MRA) 影响心脏和全身通路,与心房 (AF) 和心房 (AFL) 有关,包括纤维化和炎症.
- 了解MRA对AF/AFL发病率的影响对于治疗心脏-脏-代谢 (CKM) 疾病患者至关重要.
研究的目的:
- 评估非类固醇MRAfinerenone在预防新发性AF/AFL的疗效.
- 通过对临床试验的综合分析,在多种心脏-脏-代谢 (CKM) 谱中评估芬瑞对发生的AF/AFL的影响.
主要方法:
- 一个参与者层面的综合分析,包括来自FIDELIO-DKD,FIGARO-DKD和FINEARTS-HF试验的14581名患者.
- 患者被随机分配,接受芬龙或安慰剂.
- 新出现的AF/AFL被前性地判定,并使用Cox回归模型分析风险.
主要成果:
- 总共有631名 (4.3%) 患者在平均随访2.9年期间发展出新发性AF/AFL.
- 与安慰剂相比,使用费内伦与新发性AF/AFL的风险降低有关 (HR:0.83;95%CI:0.71-0.97;P=0.019).
- 风险降低在不同数量的CKM条件和个体试验中是一致的.
结论:
- 非类固醇MRAfinerenone显示,显著降低了新发动的心房动/心房的风险.
- 这种益处在整个心脏-脏-代谢条件的频谱中被观察到,这表明finerenone具有广泛的治疗作用.
- 新发性AF/AFL独立预测心血管死亡,心力衰竭住院和脏不良结果的后续风险增加.
相关概念视频
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:11Renal Failure: Dose Adjustments
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...